Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

The overall 5-year survival of gastric cancer (GC) has change only little in the last decades
and it remains the fifth leading cause of cancer-related death worldwide. However, in the …

Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …

Gastric cancer remains a considerable health burden throughout the world. The Cancer
Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with …

The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in
recent years. We have reviewed the recent data of clinical trial incorporating targeted …

Perioperative or postoperative adjuvant chemotherapy without radiation therapy remains the
standard of care in gastric cancer. Addition of docetaxel to adjuvant S-1 will likely emerge as …

Gastric cancer is one of the most common cancers and one of the most frequent causes of
cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have …

No standard adjuvant or palliative chemotherapy regimen has been internationally
approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is …

Abstract Purpose of Review Gastric adenocarcinoma is the fifth most common and the third
most lethal cancer worldwide. Surgery is the only chance of cure, but recurrence is common …

Remarkable developments in immuno-oncology have changed the landscape of gastric
cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response …